Novel method of analysis and measurement of the distribution or reserve of the coronary blood flow

• US 20060173301A1
• Filed: 08/18/2005
• Published: 08/03/2006
• Est. Priority Date: 01/06/2005
• Status: Abandoned Application

• Current Assignee: Yves Darlas
• Original Assignee: Yves Darlas
• Inventors: Darlas, Yves
• Application Number:
  US11/206,397
• Publication Number:
  US 20060173301A1
• Time in Patent Office: Days
• US Class Current: 600/436
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 6/481 involving the use of contrast agents
• CPC Class Codes: A61B 6/504 for diagnosis of blood vessels, e.g. by angiography
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: A61B 8/06 Measuring blood flow measuring volume flow in general G01F, e.g. G01F1/66, G01F1/72; measuring speed of fluids in general G01P5/00

Abstract

The present invention relates to the field of the essentials of life and, more particularly, to the field of biological analysis. More particularly it relates to a method for the analysis, detection and/or prognosis of disturbances of blood flow in the different regions of the organism, in patients capable of demonstrating alterations in blood flow in different organs of the body, in particular in coronary flow, in which the blood flow is measured before and after a physical, medicinal and/or neurosensory stimulation test, which modifies the blood flow in the region considered after administration of a tracer the fixation of which is measured, so that its elimination rate is determined with respect to a control value using calculation software. Use for testing cerebral, cardiac or tumorous vascularization disturbances.

Claims

1. A method for the analysis, detection and/or prognosis of disturbances of circulatory flow in the different regions of an organism comprising measuring blood flow before and after a physical, medicinal and/or neurosensory stimulation test, which modifies the blood flow, after administration of a tracer and measuring the fixation and circulation of, the tracer so that its elimination rate is determined with respect to a control value using calculation software.

2. The method for the analysis, detection and/or prognosis of disturbances of the blood flow of claim 1, wherein the target parameter is the coronary blood flow and which consists of measuring said flow before and after administration of a product which modifies the coronary flow or after an exertion, by using a tracer, and measuring the fixation and the circulation of the tracer which allows the determination of a tissue fixation rate with respect to a control value using calculation software.

3. The analysis method of claim 1, wherein the tracer is a gamma ray emitter.

4. The analysis method of claim 1 wherein the gamma ray emitter is a positon emitter.

5. The analysis method of claim 1, wherein the tracer is a fluorescent product.

6. The analysis method of claim 1 wherein the tracer is a contrast product.

7. The analysis method of claim 6, wherein the contrast product is an iodinated product.

8. The analysis method of claim 1 wherein the tracer is a contrast product which is visible by MRI.

9. The analysis method of claim 8 wherein the contrast product which is visible by MRI is a derivative of gadolinium.

10. The analysis method of claim 1 wherein the contrast product is a product which is detectable by ultrasonography or by ultrasonic Doppler effect.

11. The analysis method of claim 1 wherein the fixation of the tracer is measured using an X-ray imaging device, selected from the group consisting of gamma cameras, X-ray scanners, positron emission tomography cameras, and an MRI imaging device.

12. The analysis method of claim 1 wherein the product which modifies the coronary flow is chosen from compounds which increase coronary flow and products which reduce coronary flow.

13. The analysis method of claim 12, wherein the product which increases coronary flow is selected from the group consisting of dipyridamole, adenosine and dobutamine.

14. The analysis method of claim 12, wherein the product which reduces coronary the flow is atropine or its derivative.

15. The analysis method of claim 1 wherein the tracer is a radio-pharmaceutical tracer, a positon emitter or an isotope of thallium.

16. The analysis method of claim 15, wherein the radio-pharmaceutical tracer is selected from the group consisting of derivatives of technetium T_c⁹⁹, radioactive isotopes of indium and radioactive isotopes of iodine.

17. The analysis method of claim 15 wherein the radioactive tracer is a tracer labelled with metastable technetium T_c⁹⁹, called tetrafosmine.

19. The analysis method of claim 1 wherein the control value is that of coronary flow reserve, before or after an exertion test or pharmacological treatment.

20. The analysis method of claim 1 wherein the blood flow in the tumorous tissues is measured, before and after injection of a radio-pharmaceutical tracer.

18. The analysis method of the calculation software is that filed at the Program Protection Agency under the number IDDN FR 001-150011-000-SP2004/00 and called “

CORYFLOW”

.

21. (canceled)

22. A method of studying organic disorders linked to vascularization of brain, heart or tumorous tissues in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a tracer, measuring blood flow before and after a stimulation test and measuring the fixation and circulation of the tracer to determine its elimination rate with respect to a control value with calculation software called CORYFLOW.